; and (B) whether any changes to payment under such payment systems would decrease— (i) the number of drugs and biologicals on such shortage list; or (ii) the frequency with which the drugs and biologicals appear on such shortage list; and (2) submit to Congress recommendations for legislation and administrative actions with respect to the matters described in subparagraphs (A) and (B) of paragraph (1).